How to Finance a Drug Testing Business Acquisition

From SBA 7(a) loans to seller earnouts, understand the capital structures used to acquire DOT-compliant drug testing and MRO service companies in the $1M–$5M revenue range.

Find Drug Testing Services Deals SBA Calculator →

Drug testing businesses are strong SBA financing candidates due to their recurring employer contract revenue, non-discretionary regulatory demand, and asset-light operations. Most lower middle market deals in this space close with a blended stack combining an SBA 7(a) loan, a seller note tied to client retention, and 10–15% buyer equity. Buyers should isolate true collection and MRO margin from pass-through lab charges before sizing debt service, as inflated top-line revenue can obscure actual cash flow available to service acquisition debt.

Financing Options for Drug Testing Services Acquisitions

SBA 7(a) Loan

$500K–$3.5MPrime + 2.75%–3.25% (variable); approximately 10.5%–11.5% as of 2024

The most common financing vehicle for drug testing acquisitions, covering goodwill, client lists, equipment, and working capital. Lenders value recurring employer contracts and DOT consortium revenue as stable cash flow indicators.

Pros

Low equity injection of 10–15% preserves buyer capital for post-close investments in technology and staffing
Up to 10-year terms reduce monthly debt service relative to conventional loans, improving DSCR on recurring collection fee revenue
Goodwill and client list value are financeable, which is critical when tangible assets are limited to collection equipment and vehicles

Cons

×Lenders will scrutinize revenue concentration; accounts exceeding 20% of collections volume may trigger additional reserve requirements
×Personal guarantee required, exposing buyer assets if post-close client attrition reduces cash flow below debt service thresholds
×SBA process takes 60–90 days, which can disadvantage buyers competing against PE-backed strategic acquirers moving faster

Seller Financing with Earnout

$75K–$500K seller note; earnout up to 10–15% of deal value5%–7% on seller note; earnout metrics tied to retained revenue thresholds

Seller holds a subordinated note of 5–10% of purchase price, often paired with a 12–24 month earnout tied to employer client retention post-close. Common when owner manages key corporate or DOT consortium accounts personally.

Pros

Reduces upfront equity requirement and signals seller confidence in business durability and client stickiness post-transition
Earnout structure aligns seller incentives during transition, keeping them engaged in client introductions and MRO handoffs
Bridges valuation gaps when buyers discount month-to-month employer contracts that sellers value as de facto recurring revenue

Cons

×Earnout disputes are common if client retention metrics are poorly defined or tied to factors outside seller's post-close control
×Seller note is subordinate to SBA debt, limiting its value as credit enhancement with senior lenders
×Extended seller involvement can complicate buyer authority over operational changes, pricing, or lab vendor renegotiations

Equity Rollover (PE-Backed Roll-Up)

Seller retains equity valued at $150K–$800K depending on deal size and platform valuationNo current yield; return realized at platform exit or dividend recapitalization

Seller retains 10–20% minority equity stake in a platform acquiring multiple drug testing businesses. Common in strategic roll-ups led by national occupational health networks or background screening companies seeking regional collection density.

Pros

Seller participates in platform upside if the roll-up achieves higher exit multiples through bundled occupational health service offerings
Reduces all-cash requirement at close, making larger acquisitions feasible for PE sponsors targeting $3M–$5M EBITDA businesses
Retaining the seller as a minority owner supports client relationship continuity, reducing post-close attrition risk on key DOT accounts

Cons

×Seller liquidity is deferred and dependent on PE platform exit timeline, typically 4–7 years post-acquisition
×Minority equity offers limited control; sellers cede pricing, vendor, and operational decisions to the acquiring platform
×Valuation of retained equity is complex and often negotiated at a discount to headline deal price, reducing effective consideration

Sample Capital Stack

$2,000,000 (approximately 4.5x EBITDA on a $444K EBITDA drug testing business with diversified employer contracts)

Purchase Price

Approximately $17,500/month in combined SBA and seller note payments, assuming 10-year SBA term at 11% and 5-year seller note

Monthly Service

Approximately 1.45x based on $444K EBITDA less $305K annual debt service, meeting most SBA lender minimums of 1.25x

DSCR

SBA 7(a) loan: $1,600,000 (80%) | Seller note at 6% over 5 years: $200,000 (10%) | Buyer equity injection: $200,000 (10%)

Model your own deal structure →

Lender Tips for Drug Testing Services Acquisitions

1Separate collection fee revenue from pass-through lab and MRO charges in your financial package; lenders underwrite EBITDA on true service margin, not gross revenue inflated by lab cost pass-throughs.
2Document all DOT certifications, SAMHSA lab relationships, and compliance history upfront; SBA lenders and their credit committees treat unresolved regulatory citations as deal-level risk factors requiring reserves or price reductions.
3Prepare a client concentration analysis showing no single employer account exceeds 20% of collection volume; revenue concentration above this threshold triggers lender scrutiny and may require escrow or earnout provisions.
4Engage a healthcare-focused SBA lender with prior occupational health or laboratory services deal experience; generalist lenders often misunderstand MRO revenue streams and undervalue the recurring nature of DOT consortium management contracts.

Frequently Asked Questions

Can I use an SBA 7(a) loan to acquire a drug testing business if most client contracts are month-to-month?

Yes. SBA lenders evaluate historical retention rates and employer relationship tenure, not just contract length. Documented low churn across DOT and employer accounts often satisfies lender cash flow durability requirements even without multi-year agreements.

How do lenders treat pass-through lab revenue when sizing an SBA loan for a drug testing acquisition?

Lenders exclude pass-through lab charges from EBITDA calculations and underwrite only net collection and MRO service margins. Buyers must present restated financials that clearly isolate true operating cash flow from gross revenue.

What equity injection is typically required to acquire a $2M drug testing business with SBA financing?

Most SBA lenders require 10–15% buyer equity, or $200K–$300K on a $2M deal. A seller note of 5–10% can count toward the injection if the lender approves standby terms during the SBA loan repayment period.

Is an earnout common in drug testing acquisitions, and how should retention metrics be structured?

Earnouts are common when the seller manages key DOT consortium or employer accounts personally. Structure metrics around retained gross margin from named accounts over 12–24 months, not total revenue, to avoid disputes from pricing or lab cost changes.

More Drug Testing Services Guides

Buy a Drug Testing Services Business →Valuation Guide →SBA Loan Guide →Deal Structure →Common Mistakes →SBA Calculator →Deal Structure Builder →

Ready to finance your Drug Testing Services acquisition?

DealFlow OS surfaces acquisition targets and helps you structure the deal. Free to join.

Start finding deals — free

No credit card required